Bristol-Myers Squibb

FDA Rejects Replimune's Cancer Therapy RP1 Again, Citing Manufacturing Concerns

Replimune's stock dropped 64% after the FDA rejected its cancer therapy RP1 for a second time due to manufacturing issues. The setback could delay the therapy's approval and impact the company's development pipeline.